TTY and the international company will jointly develop the overseas market for the Liposome product, "Amphotericin B" and "Doxorubicin HCL.” The Upfront Fee for each product will be US$500,000. There will be three separate milestone payments, each at the amount of US$ 1,000,000. The profit sharing will be determined after products are launched in the market.